To appraise the clinical and cost-effectiveness of ADI-PEG 20 in combination with pemetrexed and cisplatin within its marketing authorisation for mesothelioma
Status Awaiting development
Technology type Medicine
Decision None selected
Process STA Standard
ID number 1575

Email enquiries


Key events during the development of the guidance:

Date Update
09 April 2024 Awaiting development. Following on from advice received from the company, timelines for this appraisal are to be confirmed whilst the company confirm their regulatory filing plans. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
01 March 2024 Please note that following on from conversations between NICE and the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
08 May 2019 In progress. Referred 17 October 2018

For further information on our processes and methods, please see our CHTE processes and methods manual